阿美替尼上市后不良反应分析

doi:10.19803/j.1672-8629.20240089

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (6): 683-686.
DOI: 10.19803/j.1672-8629.20240089

阿美替尼上市后不良反应分析

孙雪林¹, 杜娇², 谭琴³, 胡欣¹, 张亚同¹, 郑丽^4,*

¹北京医院药学部,国家老年医学中心,中国医学科学院老年医学研究院,北京 100730;
²青岛市市立医院,山东青岛 266000;
³北京医院生物治疗中心,国家老年医学中心,中国医学科学院老年医学研究院,北京100730;
⁴中国航天科工集团七三一医院药学部,北京 100074

收稿日期:2024-02-02 出版日期:2024-06-15 发布日期:2024-06-18
通讯作者: ^*郑丽,女,博士,主管药师,循证医学与医学信息学。E-mail：zhenglis1270755@163.com
作者简介:孙雪林,女,博士,副主任药师,药物警戒与老年合理用药。
基金资助:
中央高水平医院临床科研业务费资助项目（BJ-2023-200）; 七三一医院院级科研基金（2022-QSYN-01）; 国家自然科学基金资助项目（82373272）

Analysis of post-marketing adverse reactions of ametinib

SUN Xuelin¹, DU Jiao², TAN Qin³, HU Xin¹, ZHANG Yatong¹, ZHENG Li^4,*

¹Department of Pharmacy, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China;
²Qingdao Municipal Hospital, Qingdao Shandong 266000, China;
³Center of Biotherapy, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China;
⁴Department of Pharmacy, China Aerospace Science & Industry Corporation 731 Hospital, Beijing 100074, China

Received:2024-02-02 Online:2024-06-15 Published:2024-06-18

摘要/Abstract

摘要： 目的分析第三代表皮生长因子受体-酪氨酸激酶抑制剂（epidermal growth factor receptor-tyrosine kinase inhibitor, EGFR-TKI）阿美替尼不良反应发生的规律及特点,为该药临床安全使用提供参考。方法计算机检索 PubMed、Embase、Web of Science、The Cochrane Library、中国知网、万方数据和中国生物医学文献服务系统数据库,对阿美替尼上市后不良反应文献进行分析,检索时限为建库至 2024 年 1 月16日。结果共纳入12篇文献,收集263名患者的安全性数据,据文献数据统计,阿美替尼所致不良反应共246例次,主要表现为皮疹/痤疮样皮疹（17.9%）、转氨酶增高（12.6%）、血液及淋巴系统疾病（6.1%）、全身乏力（5.7%）、甲沟炎（7.3%）等,共发生11例≥3级的不良反应,预后良好。结论阿美替尼的不良反应表现多样,对皮肤和肝功能的影响较为明显,应持续加强用药监测,警惕其不良反应发生。

关键词: 阿美替尼, 表皮生长因子受体-酪氨酸激酶抑制剂, 非小细胞肺癌, 不良反应, 文献分析, 合理用药

Abstract: Objective To analyze the incidence of adverse reactions of the third-generation EGFR-TKI aumolertinib, and to provide reference for rational use of the drug in clinic. Methods PubMed, Embase, Web of Science, The Cochrane Library, CNKI, and WanFang Data and SinoMed database were searched to retrieve the literature on post-marketing adverse reactions of aumolertinib that was published from the inception to 16 January 2024 and to perform statistical analyses. Results A total of 12 articles were included in the study, and data on safety was collected from 263 patients. There were 246 adverse reactions caused by ametinib, which were mainly manifested as rash/acne-like rash (17.9%), increased transaminases (12.6%), onychomycosis (7.3%), haematological and lymphatic system disorders (6.1%), and generalized malaise (5.7%). A total of 11 adverse reactions ≥ grade 3 occurred, and the prognosis was good. Conclusion The adverse reactions of aumolertinib have diverse manifestations, and the effect on the skin and liver function is more obvious. Clinicians are advised to be alert to the occurrence of adverse reactions.

Key words: aumolertinib, EGFR-TKI, non-small cell lung cancer, adverse reactions, literature analysis, rational drug use

中图分类号:

R994.11

孙雪林, 杜娇, 谭琴, 胡欣, 张亚同, 郑丽. 阿美替尼上市后不良反应分析[J]. 中国药物警戒, 2024, 21(6): 683-686.

SUN Xuelin, DU Jiao, TAN Qin, HU Xin, ZHANG Yatong, ZHENG Li. Analysis of post-marketing adverse reactions of ametinib[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 683-686.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.zgywjj.com/CN/10.19803/j.1672-8629.20240089

https://www.zgywjj.com/CN/Y2024/V21/I6/683

参考文献

[1] Oncology Society of Chinese Medical Association, Chinese Medical Association Publishing House. Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)[J]. Chin J Oncol, 2023, 45(7): 539-574.
[2] LAHIRI A, MAJI A, POTDAR PD, et al.Lung cancer immunotherapy: progress, pitfalls, and promises[J]. Mol Cancer, 2023, 22(1): 40.
[3] SHI Y, AU JS, THONGPRASERT S, et al.A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)[J]. J Thorac Oncol, 2014, 9(2): 154-162.
[4] HUANG JX, WANG H.Targeted therapy and mechanism of drug resistance in non-small cell lung cancer with epidermal growth factor receptor gene mutation[J]. Chin J Lung Cancer(中国肺癌杂志), 2022, 25(3): 183-192.
[5] HOU J, SUN J, DENG XY, et al.Application of aumolertinib for epidermal growth factor receptor mutationpositive non-small cell lung cancer[J]. Central South Pharmacy, 2022, 20(8): 1856-1860.
[6] YANG J CH, CAMIDGE D R, YANG CT, et al.Safety, Efficacy, and pharmacokinetics of almonertinib (HS-10296) in pretreated patients with EGFR-mutated advanced NSCLC: a multicenter, open-label, Phase 1 Trial[J]. Journal of Thoracic Oncology, 2020, 15(12): 1907-1918.
[7] LU S, WANG Q, ZHANG G, et al.Efficacy of aumolertinib (HS-10296) in patients with advanced EGFR T790M + NSCLC: updated post-national medical products administration approval results from the APOLLO registrational trial[J]. J Thorac Oncol, 2022, 17(3): 411-422.
[8] YANG GX, CHENG YT, LIU LL, et al.Clinical trial of ametinib tablets combined with bevacizumab injection in the treatment of advanced non - small cell lung cancer patients with epidermal growth factor receptor mutation[J]. Chin J Clin Pharmoco, 2023, 39(11): 1528-1532.
[9] WANG HF, WANG Y, LI YR, et al.A case of Stevens-Johnson syndrome caused by almonertinib[J]. Chin J Hosp Pharm, 2023, 11: 1296-1298.
[10] OUYANG LH, HE GF, HUANG JJ, et al.A medication analysis of rhabdomyolysis after amitinib in patients with lung cancer[J]. Central South Pharmacy, 2022, 20(6): 1463-1466.
[11] LI TX, GUO XX, CHEN Y.A case of interstitial lung disease in a patient with non-small cell lung cancer due to targeted therapy with alectinib[J]. China Pharmacist, 2022, 25(11): 2000-2001.
[12] JIAO CC, ZHOU F, CHEN WX, et al.The efficacy of almonertinib in the second line treatment of patients with NSCLC harbo-ring EGFR mutations[J]. Modern Oncology, 2022, 30(24): 4462-4466.
[13] HUANG ZD.Neoadjuvant aumonertinib in potential resectable stage III EGFRmutation-positive lung adenocarcinom[D]. Nanchang: Nanchang University, 2023.
[14] HUANG JX.To observe the clinical efficacy of almonertinib in the treatment of patients with advanced lung adenocarcinoma[D]. Guangzhou: Southern Medical University, 2023.
[15] HAN SS, CAI J, MA JA.Analysis of cutaneous adverse drug reactions induced by epidermal growth factor receptor inhibitors in 116 patients with non small cell lung cancer[J]. Pharmaceutical and Clinical Research, 2023, 31(5): 458-461.
[16] HAN Q, SU FY, SONG ZC, et al.Clinical trial of amitinib tablets in the treatment of patients with advanced non-small cell lung cancer[J]. Chin J Clin Pharmacol, 2022, 38(15): 1723-1726.
[17] ZHOU Q, HU Z, LI X, et al.Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality[J]. BMC Pulm Med, 2023, 23(1): 79.
[18] LI T, CHANG KJ, QIU X, et al.A pilot study of anlotinib with third-generation epidermal growth factor receptor tyrosine kinase inhibitors in untreated EGFR-mutant patients with advanced non-small cell lung cancer[J]. Translational Lung Cancer RESEARCH, 2023, 12(6):1256-1263.
[19] JIANG T, LUO YY, WANG BB.Almonertinib-induced interstitial lung disease A case report[J]. Medicine, 2021, 100(3): e24393.
[20] Chinese Society of Clinical Oncology. The 2023 edition of the Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of NSCLC(中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南2023年版)[M]. Beijing: People’s Medical Publishing House, 2023.
[21] U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v5.0[EB/OL]. (2017-11-27)[2024-04-24]. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50.
[22] CHANG HC, WANG TJ, LIN MH, et al.A review of the systemic treatment of Stevens-Johnson syndrome and toxic epidermal Necrolysis[J]. Biomedicines, 2022, 10(9): 2105.
[23] GARG VK, BUTTAR HS, BHAT SA, et al.stevens-johnson Syndrome and toxic epidermal necrolysis: an overview of diagnosis, Therapy Options and Prognosis of Patients[J]. Recent Adv Inflamm Allergy Drug Discov, 2023, 17(2): 110-120.
[24] TORRES PA, HELMSTETTER JA, KAYE AM, et al.Rhabdomyolysis: pathogenesis, diagnosis, and treatment[J]. Ochsner J, 2015, 15(1): 58-69.
[25] GUPTA A, THORSON P, PENMATSA KR, et al.Rhabdomyolysis: revisited[J]. Ulster Med J, 2021, 90(2): 61-69.

阿美替尼上市后不良反应分析

Analysis of post-marketing adverse reactions of ametinib

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	潘知玉, 朱健, 于亚南, 刘骏, 姜燕华, 钱真真, 吴广, 王忠, 武红莉, 荆志伟. 3010例芪蛭通络胶囊的真实世界安全性研究[J]. 中国药物警戒, 2024, 21(6): 660-665.
[2]	邵波, 徐丽丽, 朱兰, 刘硕, 万浩, 黄光瑞. 湿毒清制剂肝损伤风险分析及思考[J]. 中国药物警戒, 2024, 21(6): 666-670.
[3]	高旭, 彭金娥, 范子博, 张伟. 利福平致溶血性贫血临床特征与预后结局的系统评价[J]. 中国药物警戒, 2024, 21(6): 671-676.
[4]	阿拉腾花, 高磊, 张晓朦, 张冰. 基于蒙医药学古籍文献探析蒙药药物警戒科学内涵[J]. 中国药物警戒, 2024, 21(6): 677-682.
[5]	林彦馨, 刘艳辉, 董婧, 姚佳晨, 李文艳. 1例伊立替康致结肠癌患者急性肝损伤的药学监护[J]. 中国药物警戒, 2024, 21(6): 693-696.
[6]	徐钰行, 弓清梅, 骆宇琛, 王宗隅, 张囝. 膀胱内灌注卡介苗致多器官功能衰竭1例分析[J]. 中国药物警戒, 2024, 21(6): 697-699.
[7]	唐祯菊, 龙小换, 王意军, 黄愉腾, 王卫亮. 甲苯磺酸多纳非尼片致多形红斑型药疹1例分析[J]. 中国药物警戒, 2024, 21(6): 700-702.
[8]	刘天睿, 李瑶, 陈瑜鑫, 李慧, 高海云, 袁媛. 7种常见易发生不良反应真菌的毒性分析及安全应用[J]. 中国药物警戒, 2024, 21(5): 489-495.
[9]	高海云,陈瑜鑫,李瑶,李慧,刘天睿,袁媛. 毛头鬼伞的本草考证及不良反应研究进展[J]. 中国药物警戒, 2024, 21(5): 502-506.
[10]	李文鹏, 刘明煜, 曹颖, 周虎子威, 王胜锋. 阿片类药物全球滥用的监管现状及研究进展[J]. 中国药物警戒, 2024, 21(5): 513-518.
[11]	李文鹏, 周虎子威, 朱兰, 王胜锋. 阿片类药物需要量的估算方法及应用进展[J]. 中国药物警戒, 2024, 21(5): 519-523.
[12]	于静, 帕拉提·热合曼, 赵婷, 冯继荣, 孙岩, 何磊. 拉考沙胺治疗4岁以下癫痫患儿疗效、安全性与血药浓度的相关性研究[J]. 中国药物警戒, 2024, 21(5): 559-562.
[13]	刘翠丽, 吴晨, 王涛. 吡拉西坦制剂安全性风险分析及思考[J]. 中国药物警戒, 2024, 21(5): 563-566.
[14]	武一,何金阳,王晓剑,周效竹,刘冉佳,郭明星,赵莹,代文迪,崔向丽. 基于美国VAERS数据库的肝、肾移植受者接种新型冠状病毒疫苗不良事件分析[J]. 中国药物警戒, 2024, 21(5): 572-579.
[15]	苏小涵, 曾姣, 李雪, 刘礼鑫, 侯令密, 李金穗. 基于美国FAERS数据库的乳腺癌患者使用阿贝西利不良事件分析[J]. 中国药物警戒, 2024, 21(5): 580-586.